Literature DB >> 25869350

Diagnostic Performance of Coronary CT Angiography and Myocardial Perfusion Imaging in Kidney Transplantation Candidates.

Simon Winther1, My Svensson2, Hanne Skou Jørgensen2, Kirsten Bouchelouche3, Lars Christian Gormsen3, Birgitte Bang Pedersen4, Niels Ramsing Holm5, Hans Erik Bøtker5, Per Ivarsen2, Morten Bøttcher6.   

Abstract

OBJECTIVES: The goal of this study was to compare the diagnostic accuracy of the coronary artery calcium score (CACS), coronary computed tomography angiography (CTA), single-photon emission computed tomography (SPECT), and a combination of these tools in the diagnosis of obstructive coronary artery disease (CAD) in patients with chronic kidney disease referred for cardiac evaluation before kidney transplantation.
BACKGROUND: The optimal method for the detection of obstructive CAD in potential kidney transplant patients has not yet been identified. Previous studies have found that established noninvasive stress tests have low diagnostic accuracy, while the diagnostic performance of coronary CTA remains unknown.
METHODS: We prospectively studied 138 patients referred for pre-transplant cardiac evaluation (mean age 54 years; age range 22 to 72 years; 68% male; 43% treated with dialysis). All patients underwent CACS, coronary CTA, SPECT, and invasive coronary angiography. The results of the noninvasive tests were merged into integrated hybrid imaging results: Hybrid (CACS/SPECT) and Hybrid (coronary CTA/SPECT).
RESULTS: The overall prevalence of obstructive CAD (≥50% reduction in luminal diameter) according to quantitative invasive coronary angiography was 22%. Two-thirds of the patients with obstructive CAD had a stenosis located in a proximal coronary segment. In a patient-level model, the sensitivity and specificity, respectively, for diagnosing obstructive CAD were as follows: CACS (threshold of 400), 67% and 77%; coronary CTA, 93% and 63%; SPECT, 53% and 82%; Hybrid (CACS/SPECT), 33% and 97%; and Hybrid (coronary CTA/SPECT), 67% and 86%. The sensitivity for diagnosing obstructive CAD in a proximal segment was 70% for CACS (threshold 400), 100% for coronary CTA, 60% for SPECT, 40% for Hybrid (CACS/SPECT), and 75% for Hybrid (coronary CTA/SPECT).
CONCLUSIONS: Coronary CTA is a reliable test with high sensitivity and a high negative predictive value for diagnosing obstructive CAD before kidney transplantation. A noninvasive approach with use of either coronary CTA or a combination of coronary CTA and SPECT to rule out obstructive CAD seems recommendable in kidney transplant candidates. (ACToR-Study: Angiographic CT of Renal Transplantation Candidate-Study; NCT01344434).
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary angiography; coronary computed tomography angiography; renal transplantation; sensitivity and specificity; single-photon emission computed tomography

Mesh:

Year:  2015        PMID: 25869350     DOI: 10.1016/j.jcmg.2014.12.028

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  27 in total

1.  Stress testing in patients with chronic kidney disease: The need for ancillary markers for effective risk stratification and prognosis.

Authors:  Sripal Bangalore
Journal:  J Nucl Cardiol       Date:  2015-08-22       Impact factor: 5.952

2.  The diagnostic accuracy of stress myocardial perfusion scintigraphy in patients with end-stage renal disease.

Authors:  Ahmed Fathala; Mohammed Alqattan; Riyadh Alsalloum
Journal:  Am J Cardiovasc Dis       Date:  2021-04-15

Review 3.  Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies.

Authors:  Alexandru Burlacu; Simonetta Genovesi; Carlo Basile; Alberto Ortiz; Sandip Mitra; Dimitrios Kirmizis; Mehmet Kanbay; Andrew Davenport; Frank van der Sande; Adrian Covic
Journal:  J Nephrol       Date:  2020-05-29       Impact factor: 3.902

4.  Hybrid anatomo-functional imaging of coronary artery disease: Beneficial irrespective of its core components.

Authors:  Francesco Nudi; Giuseppe Biondi-Zoccai; Andrea Romagnoli; Orazio Schillaci; Alessandro Nudi; Francesco Versaci
Journal:  J Nucl Cardiol       Date:  2018-12-18       Impact factor: 5.952

Review 5.  Addressing Knowledge Gaps in the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a Review of Recent Coronary Artery Calcium Literature.

Authors:  Vasanth Sathiyakumar; Roger S Blumenthal; Khurram Nasir; Seth S Martin
Journal:  Curr Atheroscler Rep       Date:  2017-02       Impact factor: 5.113

6.  Diagnostic Performance of Hybrid Cardiac Imaging Methods for Assessment of Obstructive Coronary Artery Disease Compared With Stand-Alone Coronary Computed Tomography Angiography: A Meta-Analysis.

Authors:  Asim Rizvi; Donghee Han; Ibrahim Danad; Bríain Ó Hartaigh; Ji Hyun Lee; Heidi Gransar; Wijnand J Stuijfzand; Hadi Mirhedayati Roudsari; Mahn Won Park; Jackie Szymonifka; Hyuk-Jae Chang; Erica C Jones; Paul Knaapen; Fay Y Lin; James K Min; Jessica M Peña
Journal:  JACC Cardiovasc Imaging       Date:  2017-08-16

Review 7.  Cardiovascular disease in patients with chronic kidney disease.

Authors:  Turgay Saritas; Jürgen Floege
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

8.  Prognostic impact of SPECT-MPI after renal transplantation.

Authors:  Wael Abuzeid; Robert M Iwanochko; Xuesong Wang; S Joseph Kim; Mansoor Husain; Douglas S Lee
Journal:  J Nucl Cardiol       Date:  2016-09-23       Impact factor: 5.952

Review 9.  Coronary Revascularization in Patients with CKD Stage 5D: Pragmatic Considerations.

Authors:  Gautam R Shroff; Charles A Herzog
Journal:  J Am Soc Nephrol       Date:  2016-08-04       Impact factor: 10.121

10.  The Incremental Diagnostic Performance of Coronary Computed Tomography Angiography Added to Myocardial Perfusion Imaging in Patients with Intermediate-to-High Cardiovascular Risk.

Authors:  Pei-Ying Hsu; Wen-Jeng Lee; Mei-Fang Cheng; Ruoh-Fang Yen; Kai-Yuan Tzen; Yen-Wen Wu
Journal:  Acta Cardiol Sin       Date:  2016-03       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.